Word

GENOSCIENCE PHARMA

Status

Registered

Status Code

700

Status Date

Tuesday, August 25, 2020

Serial Number

79258665

Registration Number

6132420

Registration Date

Tuesday, August 25, 2020

Mark Type

4000

Filing Date

Friday, February 1, 2019

Published for Opposition

Tuesday, June 9, 2020

Trademark Owner History

GENOSCIENCE PHARMA - Original Registrant

Classifications

1 Active chemical ingredients used in the manufacture of anti-cancer drugs; chemical products intended for pharmaceutical sciences, namely, chemical additives for use in the manufacture of pharmaceuticals; preserving agents for the pharmaceutical industry, namely, preservatives for use in the pharmaceutical industry; antioxidants for the manufacture of pharmaceutical products; chemical preparations for be used in the manufacture of pharmaceutical products, namely, active chemical ingredients for use in the manufacture of pharmaceuticals for treating cancer-related diseases or conditions; chemicals for use in biotechnological product development; enzymes derived from biotechnological processes for industrial use; chemicals used in biotechnological manufacturing processes; diagnostic preparations and diagnostic reagents for scientific or research use; reagents and solvents for sample preparation, modification and manipulation of cells, as well as for the implementation of marking methods, separation, isolation, reproduction and/or cleaning of biopolymers, nucleic acids, proteins, macromolecules, namely, reagents for scientific use and biologically active substances for diagnostic use, namely, biologically active enzymes and microorganisms that are aimed as sanitizing water environments and to treat the activation and optimization of biological filter systems

5 Pharmaceutical preparations, pharmaceutical products, and pharmaceutical substances, namely, pharmaceutical preparations for the treatment of cancer-related diseases or conditions; pharmaceutical preparations for cancer treatment; biopharmaceutical products for cancer treatment, namely, biological preparations for the treatments of cancer; pharmaceutical products for cancer treatment; pharmaceutical preparations and substances for cancer prevention; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparations for cancer prevention and treatment; biotechnological preparations for medical use, namely, biological tissue cultures for medical purposes; diagnostic agents for medical use; strips for medical diagnosis, namely, medical diagnostic test strips for cancer diagnosis; diagnostic preparations for medical use; diagnostic reagents for medical use; diagnostic substances for medical use; pharmaceutical medicine products and diagnostic products for sample preparation, modification and manipulation of cells and for marking, separation, isolation, reproduction and/or cleaning of biopolymers, nucleic acids, proteins, macromolecules and biologically active substances, namely, chemical reagents for medical purposes

42 Development of new technology on behalf of third parties in the field of genetics and biotechnology; biotechnological processes for regulating, modifying and characterizing of disease conditions, medical research specialized in the biotechnological field with respect to regulating, modifying and characterizing diseases or conditions; research and development for third parties in the field of biotechnology; manufacturing and consolidating upon request of DNA, biological organisms, cells, viruses, pathogens, special cells which have been genetically modified according to the specification of third parties for scientific, medical and laboratory use and for research, namely, medical and scientific laboratory services; gene therapy services for third parties, namely, scientific research and product development regarding DNA, biological organisms, cells, viruses, pathogens and special cells which have been genetically modified for scientific and medical use and for research; scientific and technological services, namely, research and design in the field of medical treatment, namely, cancer treatment; industrial analysis and research services, namely, testing, analysis and evaluation of drugs for treatment of cancer and cancer-related diseases and conditions to assure compliance with industry and regulatory standards; research and development of anti-cancer drugs; development of pharmaceutical preparations and medicines; development of pharmaceutical products; development of chemical compounds, namely, custom design and development of reagents and biochemical assays; research and development of new products for others with respect to chemical compounds for therapeutic use; pharmaceutical drug development services for anti-cancer drugs; evaluation of pharmaceutical products; research in the field of pharmaceutical products, namely, pharmaceutical research and development; pharmaceutical research and development in the field of anti-cancer drugs; pharmaceutical research and development services; pharmaceutical research; carrying out clinical trials for pharmaceutical products, namely, conducting clinical trials for others; conducting cancer treatment clinical trials for others; provision of medical and scientific research information concerning the results of clinical trials for pharmaceutical products; laboratory research services in the field of pharmaceuticals; laboratory research services for cancer treatment; testing, inspection and research services in the field of pharmaceuticals; testing, inspection and research for pharmaceuticals for cancer treatment; biotechnological research services; preparation of reports in the field of biotechnology; research and development in the field of biotechnology; services provided by consultants in the field of biotechnology, namely, scientific research consulting in the field of biotechnology; providing scientific research information in the biochemical and biotechnological fields; product design and development in the field of medical and pharmaceutical diagnostic apparatus

44 Medical analysis services for diagnosing cancer; medical analysis of RNA or DNA for cancer diagnosis and prognosis; medical analysis services for cancer diagnosis and prognosis; colorectal cancer screening services; medical services for diagnosing diseases; medical diagnosis of cancer-related diseases or conditions; medical testing for the diagnosis and treatment of persons; medical analysis services for cancer diagnosis; medical testing and analysis for diagnostic or treatment purposes

"PHARMA"
GENO SCIENCE PHARMACEUTICAL

Trademark Events

Jan 3, 2021

Final Decision Transaction Processed By Ib

Dec 16, 2020

Final Disposition Notice Sent To Ib

Dec 15, 2020

Final Disposition Processed

Nov 25, 2020

Final Disposition Notice Created, To Be Sent To Ib

Aug 25, 2020

Registered-Principal Register

Jun 9, 2020

Official Gazette Publication Confirmation E-Mailed

Jun 9, 2020

Published For Opposition

Jun 5, 2020

Notification Processed By Ib

May 20, 2020

Notification Of Possible Opposition Sent To Ib

May 20, 2020

Notice Of Start Of Opposition Period Created, To Be Sent To Ib

May 20, 2020

Notification Of Notice Of Publication E-Mailed

May 4, 2020

Approved For Pub - Principal Register

Apr 30, 2020

Teas/Email Correspondence Entered

Apr 30, 2020

Correspondence Received In Law Office

Apr 30, 2020

Teas Request For Reconsideration Received

Jan 13, 2020

Notification Of Final Refusal Emailed

Jan 13, 2020

Final Refusal E-Mailed

Jan 13, 2020

Final Refusal Written

Dec 18, 2019

Teas/Email Correspondence Entered

Dec 18, 2019

Correspondence Received In Law Office

Dec 18, 2019

Teas Response To Office Action Received

Jul 12, 2019

Refusal Processed By Ib

Jun 24, 2019

Non-Final Action Mailed - Refusal Sent To Ib

Jun 24, 2019

Refusal Processed By Mpu

Jun 4, 2019

Non-Final Action (Ib Refusal) Prepared For Review

Jun 3, 2019

Non-Final Action Written

May 24, 2019

Application Filing Receipt Mailed

May 20, 2019

Assigned To Examiner

May 20, 2019

New Application Office Supplied Data Entered In Tram

May 16, 2019

Sn Assigned For Sect 66a Appl From Ib